MedTrace Logo

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

NCT02221947 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-11-06

Study results available
· View outcomes & findings →

Summary

This study is being done to evaluate the safety, tolerability and potential effectiveness of a new investigational drug, bryostatin 1, in patients with Alzheimer's disease (AD).

Conditions

Interventions

DRUG

Bryostatin 1

25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.

DRUG

Placebo

Placebo, single dose via intravenous infusion over 1 hour.

Sponsors & Collaborators

  • Blanchette Rockefeller Neurosciences Insitute

    collaborator OTHER

  • Neurotrope Bioscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Hakop Gevorkyan, MD, MBA · California Clinical Trials Medical Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221947 on ClinicalTrials.gov